Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
SkinBioTherapeutics ( (GB:SBTX) ) just unveiled an announcement.
SkinBioTherapeutics has uncovered potential misrepresentation by its former CEO that casts serious doubt on £0.77m of accrued royalty income booked in its FY25 audited accounts, and now expects to remove this income, cutting FY25 revenue to £3.87m and widening adjusted EBITDA losses to £1.17m. While the board stresses that key contracts, core businesses Dermatonics and Bio-Tech Solutions, and AxisBiotix™ sales remain sound and cash stood at £2.92m on 13 February 2026, it has launched a broader review of financial reporting, warned that FY26 results will fall significantly below market expectations, and is moving to appoint an interim and then permanent CEO as the chairman temporarily assumes executive control.
The most recent analyst rating on (GB:SBTX) stock is a Hold with a £12.00 price target. To see the full list of analyst forecasts on SkinBioTherapeutics stock, see the GB:SBTX Stock Forecast page.
Spark’s Take on GB:SBTX Stock
According to Spark, TipRanks’ AI Analyst, GB:SBTX is a Neutral.
The score is primarily weighed down by weak financial performance: despite strong revenue growth, persistent losses and negative operating/free cash flow are significant risks. Technicals add pressure, with the stock in a broad downtrend below major moving averages and negative MACD. Valuation is constrained by a negative P/E and no dividend support.
To see Spark’s full report on GB:SBTX stock, click here.
More about SkinBioTherapeutics
SkinBioTherapeutics is a UK-based life science company focused on skin health, built around its proprietary SkinBiotix® microbiome technology developed with the University of Manchester. It targets the skin healthcare market through cosmetic skincare and gut-skin axis food supplements sold under AxisBiotix™, supported by partnerships with Croda and Superdrug and by acquisitions in complementary skincare and cosmetic applications.
Average Trading Volume: 3,029,865
Technical Sentiment Signal: Sell
Current Market Cap: £32.07M
For detailed information about SBTX stock, go to TipRanks’ Stock Analysis page.